ecancermedicalscience

ecancermedicalscience is an open access cancer journal focused on under-resourced communities. In order to help reduce global inequalities in cancer care and treatment, we provide free access to all articles from the point of publication and we only charge authors who have specific funding to cover publication costs.

The journal considers articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epidemiology, clinical reports, controlled trials (in particular if they are independent or publicly funded trials), health systems, cancer policy and regulatory aspects of cancer care.

Editor-in-Chief: Dr Eduardo Cazap, MD PhD (President SLACOM)

ISSN: 1754-6605

Submit article

868-gut-microbiota-chemotherapy-and-the-host-the-influence-of-the-gut-microbiota-on-cancer-treatment

Special Issue: Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment

Anna Louise Pouncey, Alasdair James Scott, James Leslie Alexander, Julian Marchesi, James Kinross

5 Sep 2018

https://doi.org/10.3332/ecancer.2018.868

Abstract | Full Article | PDF

864-the-implementation-of-omics-technologies-in-cancer-microbiome-research

Special Issue: The implementation of omics technologies in cancer microbiome research

Benjamin H Mullish, Laura S Osborne, Julian R Marchesi, Julie AK McDonald

5 Sep 2018

https://doi.org/10.3332/ecancer.2018.864

Abstract | Full Article | PDF

837-lasting-pathologic-complete-response-to-chemotherapy-for-ovarian-cancer-after-receiving-antimalarials-for-dermatomyositis

Case Report: Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis

Isabella Cadena, Victoria P Werth, Pascale Levine, Annie Yang, Andrea Downey, John Curtin, Franco Muggia

22 May 2018

https://doi.org/10.3332/ecancer.2018.837

Abstract | Full Article | PDF

825-evidence-on-the-cost-of-breast-cancer-drugs-is-required-for-rational-decision-making

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Anne Margreet Sofie Berghuis, Hendrik Koffijberg, Leonardus Wendelinus Mathias Marie Terstappen, Stefan Sleijfer, Maarten Joost IJzerman

16 Apr 2018

https://doi.org/10.3332/ecancer.2018.825

Abstract | Full Article | PDF

820-highlights-from-the-10th-breast-gynaecological-and-immunotherapy-international-cancer-conference-bgicc-18-19-january-2018-cairo-egypt

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Hesham El-Ghazaly, Adel Aref, Nermeen Bahie-eldin

22 Mar 2018

https://doi.org/10.3332/ecancer.2018.820

Abstract | Full Article | PDF

816-neoadjuvant-chemotherapy-in-locally-advanced-duodenal-adenocarcinoma

Case Report: Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma

Carlos Velandia, Rafael Delgado Morales, Carlos Coello, Armando Gil Mendoza, Gabriel Pérez, Emperatriz Aguero

5 Mar 2018

https://doi.org/10.3332/ecancer.2018.816

Abstract | Full Article | PDF | Spanish

797-natural-history-of-castration-resistant-prostate-cancer-in-sub-saharan-african-black-men-a-single-centre-study-of-nigerian-men

Review: Natural history of castration-resistant prostate cancer in sub-Saharan African black men: a single-centre study of Nigerian men

Jibril O Bello

16 Jan 2018

https://doi.org/10.3332/ecancer.2018.797

Abstract | Full Article | PDF

781-repurposing-drugs-in-oncology-redo-chloroquine-and-hydroxychloroquine-as-anti-cancer-agents

Clinical Study: Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents

Ciska Verbaanderd, Hannelore Maes, Marco B Schaaf, Vikas P Sukhatme, Pan Pantziarka, Vidula Sukhatme, Patrizia Agostinis, Gauthier Bouche

23 Nov 2017

https://doi.org/10.3332/ecancer.2017.781

Abstract | Full Article | PDF